Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study

BACKGROUND: In New Zealand, trastuzumab is standard therapy for human epidermal growth factor receptor-2 (HER2)-positive early and metastatic breast cancer. Given the requirement for ongoing adjuvant or maintenance treatment and intravenous (IV) delivery, such a regimen consumes considerable health...

Descripción completa

Detalles Bibliográficos
Autores principales: North, Richard T, Harvey, Vernon J, Cox, Levonne C, Ryan, Stuart N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524269/
https://www.ncbi.nlm.nih.gov/pubmed/26251623
http://dx.doi.org/10.2147/CEOR.S85599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524269/
https://www.ncbi.nlm.nih.gov/pubmed/26251623
http://dx.doi.org/10.2147/CEOR.S85599

Ejemplares similares